Vaxcyte Inc (PCVX)
$60.06
Insights on Vaxcyte Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.9% return, outperforming this stock by 9.3%
Performance
- $58.10$60.06$60.06
3.26%
Downside
Day's Volatility :3.26%
Upside
0.0%
- $41.57$82.04$60.06
30.79%
Downside
52 Weeks Volatility :49.33%
Upside
26.79%
Returns
| Period | Vaxcyte Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -6.24% | 1.1% | 0.0% |
6 Months | 24.92% | 12.5% | 0.0% |
1 Year | 43.57% | 6.9% | 2.2% |
3 Years | 185.65% | 14.3% | -23.0% |
Highlights
Market Capitalization | 6.6B |
Book Value | $13.01 |
Earnings Per Share (EPS) | -4.14 |
Wall Street Target Price | 103.29 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.24% |
Return On Equity TTM | -36.67% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -23.0M |
EBITDA | -464.9M |
Diluted Eps TTM | -4.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.31 |
EPS Estimate Next Year | -4.48 |
EPS Estimate Current Quarter | -1.07 |
EPS Estimate Next Quarter | -1.04 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 71.98%
Technicals Summary
Sell
Neutral
Buy
Vaxcyte Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Vaxcyte Inc | -9.15% | 24.92% | 43.57% | 185.65% | 185.65% |
 Moderna, Inc. | 1.34% | 41.81% | -16.73% | -38.71% | 314.51% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -4.23% | 10.39% | 23.96% | 84.71% | 131.85% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Vaxcyte Inc | NA | NA | NA | -4.31 | -0.37 | -0.24 | NA | 13.01 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Vaxcyte Inc | Buy | $6.6B | 185.65% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 314.51% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 131.85% | 29.17 | 36.68% |
Institutional Holdings
FMR Inc
13.11%BlackRock Inc
7.91%Vanguard Group Inc
7.80%RA Capital Management, LLC
7.28%HHG PLC
6.44%Wellington Management Company LLP
4.09%
Corporate Announcements
Vaxcyte Inc Earnings
Vaxcyte Inc’s price-to-earnings ratio stands at None
Read More
Company Information
sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe
Organization | Vaxcyte Inc |
Employees | 254 |
CEO | Mr. Grant E. Pickering M.B.A. |
Industry | Health Technology |
